Mode
Text Size
Log in / Sign up

Mistletoe extract plus standard treatment shows no quality of life benefit in advanced pancreatic cancerTrial shows mistletoe extract does not improve pancreatic cancer care

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that mistletoe extract provides no significant improvement in quality of life or weight for advanced pancreatic cancer.

This multicenter Phase III randomized controlled trial enrolled 290 patients with advanced pancreatic cancer and a performance status of 0 to 2. The study aimed to evaluate the impact of subcutaneous mistletoe extract added to standard treatment, which included palliative chemotherapy or best supportive care, compared to placebo plus standard treatment.

The primary outcome was quality of life, for which no statistically significant differences were observed between the treatment arms. Secondary outcomes including body weight also showed no statistically significant differences between groups. Regarding blood biomarkers, no effects were found except for a statistically significant increase in eosinophils within the mistletoe arm.

Supportive and inpatient care costs were reported as similar across both arms, though specific cost calculations were not performed. The study noted that the observed increase in eosinophils in the mistletoe group had no association with clinical effect. Safety data regarding adverse events or discontinuations were not reported.

Due to the lack of significant improvements in quality of life or weight, there is no clinical reason to recommend mistletoe extract for patients with advanced pancreatic cancer. The study provides high-certainty evidence that this intervention does not modify primary outcomes in this population.

How this fits prior evidence

How this fits prior evidence: This finding addresses a gap in supportive care options for pancreatic cancer. While previous coverage noted that high red meat consumption increases pancreatic cancer risk by 16%, and other studies explored neoadjuvant gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1, this trial specifically evaluates the role of mistletoe extract as an adjunct therapy. The results confirm that mistletoe extract does not provide a measurable benefit for quality of life in advanced cases.

Living with advanced pancreatic cancer is incredibly difficult, and many people look for any extra support to improve their daily lives. This study looked at whether adding a mistletoe extract to standard treatments, like chemotherapy, could help these patients feel better or maintain their weight.

Researchers followed 290 patients across nine different centers over a period of up to nine months. While the group receiving the mistletoe extract showed an increase in a specific type of white blood cell called eosinophils, this change did not lead to any actual clinical benefits for the patients.

Ultimately, the study found no significant differences in quality of life or body weight between those who received the mistletoe and those who received a placebo. Because no extra benefits were seen, there is currently no clinical reason to recommend mistletoe extract as an addition to standard care for pancreatic cancer.

What this means for you:
Mistletoe extract did not improve quality of life or weight for patients with advanced pancreatic cancer.

Common questions

Does mistletoe extract help with symptoms of pancreatic cancer?

The study found no statistically significant differences in quality of life between patients who received mistletoe extract and those who did not. While the treatment was tested alongside standard care, it did not provide any extra relief or improvement for the patients' daily well-being.

Does mistletoe extract help patients maintain their weight?

No significant differences were found in body weight between the two groups. Patients receiving the mistletoe extract maintained similar weights compared to those who received a placebo along with their standard treatment.

What did the blood tests show for patients taking mistletoe?

Most blood markers remained similar between both groups. The only significant change was an increase in eosinophils, which are a type of white blood cell, in the mistletoe group. However, this specific increase was not linked to any clinical benefit for the patients.

Study Details

Study typeRct
Sample sizen = 290
EvidenceLevel 2
PublishedJul 2026
View Original Abstract ↓
BACKGROUND: Mistletoe extract is a widespread complementary therapy mainly used for quality-of-life improvement in cancer patients. Advanced pancreatic cancer is associated with poor quality of life and better therapies for symptomatic relief are highly needed. AIM: MISTRAL aimed to assess the impact of mistletoe extract on quality of life, body weight, observed costs and blood biomarkers in patients with advanced pancreatic cancer. DESIGN: MISTRAL was an investigator-initiated, phase III, randomized, double-blind, placebo-controlled, parallel-group, superiority, multicenter, clinical trial with a nested biomarker study. Registration EudraCT 2014-004552-64, NCT02948309. SETTING AND PARTICIPANTS: At 9 oncology centers, 290 participants were randomized to standard treatment (palliative chemotherapy or best supportive care) plus subcutaneous mistletoe extract or placebo. Main inclusion criteria were advanced pancreatic cancer, performance status 0-2, main exclusion criteria neuroendocrine pancreatic tumor. EORTC-QLQ-C30, EORTC-QLQ-PAN26, body weight, cost parameters and biomarkers were assessed from baseline up until 9 months. RESULTS: No statistically significant differences for quality of life and weight were evident between treatment arms. Parameters for observed costs for supportive and inpatient care (days at hospital, parenteral nutrition infusions, nutritional supplement drinks, number of visits of palliative home care teams, symptom-relieving medication) were similar in both arms. Thus, calculation of costs was not performed. No effect on explored biomarkers (differential blood count, lymphocyte subpopulations, C-reactive protein, albumin and Ca19-9) was found except for a statistically significant increase of eosinophils in the mistletoe arm without association to clinical effect. CONCLUSIONS: Since no benefit was observed, there is no clinical reason to recommend mistletoe extract in patients with advanced pancreatic cancer.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.